Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.34 |
| ▸ | PTGIR | P43119 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617813 | 0.89 | SLC6A2 (0.39) | CTSKCHRM1PTGIRCYP2C19 | |
| SCHEMBL16617814 | 0.89 | SLC6A2 (0.39) | CTSKCHRM1PTGIRCYP2C19 | |
| SCHEMBL16618095 | 0.84 | CTSK (0.55) | CTSKALOX5APPTGIR | |
| SCHEMBL16617751 | 0.84 | CTSK (0.48) | CTSKALOX5APPTGIR | |
| SCHEMBL16618096 | 0.84 | CTSK (0.48) | CTSKALOX5APPTGIR | |
| SCHEMBL16617749 | 0.84 | CTSK (0.55) | CTSKALOX5APPTGIR | |
| SCHEMBL16618101 | 0.82 | CTSK (0.49) | CTSKALOX5AP | |
| SCHEMBL16616900 | 0.82 | IKBKB (0.39) | CTSKALOX5APNR4A2RXRARXRB | |
| SCHEMBL16617381 | 0.82 | IKBKB (0.39) | CTSKALOX5APNR4A2RXRARXRB | |
| SCHEMBL16618010 | 0.81 | CTSK (0.40) | CTSKALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055314-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-12 | — | — | EP | disclosed |
| US-9458181-B2 | Cathepsin cysteine protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099719-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | CTSK 4/4885CHRM1 4585/4885ALOX5AP 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.